Early Investor Opportunity!
Revealed: Major US Funds Piling Into “Tiny” Biotech Stock…
- Groundbreaking research team filing key patents in “unorthodox” mental health treatment, 4 promising drugs already in development pipeline…
- Over US$70M in operational funding already raised by leadership and visionary co-founders…
- Wall Street funds battling for top shareholder positioning…
- Recently received Phase II clinical trial approval…
If you’re looking for early investment opportunities in the promising medical psychedelic research space, and you want to position your portfolio before the wall of “dumb money” floods in…keep your eye on Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF). Interest in Cybin, a small psychedelic medical research and development outfit, is surging as global demand for alternative mental health solutions skyrockets. Over the last few months Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF), while researching alternative treatments for mental health issues like depression, PTSD, and addiction, revealed that they’ve now filed 12 key patents for new psychedelic compounds and delivery platforms.
And the profit potential could be massive for early investors… The company that holds the patent rights to the medical solution for debilitating mental health issues could capitalize on this underserved market over the next few years. Pharmaceutical companies and teams of scientists around the world are now racing to develop and control these new life saving psychedelic treatments, patents, and intellectual property. Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) looks to be the winner of the race with patents filed and four promising drugs well into the development pipeline.
A $16 Trillion Dollar Opportunity…
According to the World Health Organization, Over 700 Million people worldwide are affected with some sort of mental illness, addiction or eating disorder1. Worldwide, 1 in 4 people will suffer from mental or neurological disorders at some point in their lives2. The National Center for Biotechnology Information (NCBI) estimates3 that worldwide economic output loss from mental health issues like depression and alcohol addiction will cause $16.3 TRILLION in worldwide economic output loss between 2011 and 2030. A global economic output loss higher than cancer or diabetes.
Current treatment solutions, using expensive therapy and lengthy treatment timelines, can’t keep up with demand and or do not effectively work to treat the underlying problem.
Until now…
Recent research has revealed treatments such as psilocybin-assisted therapy and other psychedelic options are effective in treating issues such as addiction, post-traumatic stress disorder (PTSD), depression, and numerous other conditions4.
Even better, according to the published research findings, these new psychedelic solutions are producing “large, rapid, and sustained antidepressant effects in patients with major depressive disorder.”
“…on a mission to revolutionize mental healthcare.”
Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF), is on the cutting edge of this new era of mental health treatment. With a visionary leadership consisting of industry veterans and a strong research team of innovative scientists, Cybin – a “tiny” biotech company – has massive levels of output…
- 12 psychedelic related patents filed…
- 50 different proprietary psychedelic molecules developed based upon DMT, MDMA, Psilocybin, and other psychedelics…
- 4 promising active drug programs in the pipeline, with one entering “Phase II” of the development conduit…
- Leveraging tech and strategic partnerships for advancing new frontiers for treating neurological disorders…
- Aggressive M&A strategy to access broader markets and investor audiences…
- Experienced scientific team that has previously brought over 5 drugs to market, overseen 60+ IND programs with the FDA and has collectively been involved in 37 exits across the biotech sector and various other verticals…
Before listing on Canada’s NEO exchange in November 2020, top US funds like RA Capital, Janus Henderson, LifeSci Ventures and others are now major shareholders of company stock. Aiming to reach a wider investment audience, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) has become eligible on the Multijurisdictional Disclosure System (MJDS) for listing on a US Tier 1 exchange.
Under the leadership of CEO Doug Drysdale, Cybin is positioning itself to tackle the significant work that remains for creating FDA approved psychedelic drugs that control delivery and deliver quicker results with shorter duration times.
With a 30 year veteran in the healthcare sector, Drysdale has built and turned-around 4 pharmaceutical companies, completed 15 corporate acquisitions, and has raised $4 billion of both public and private capital. And according to Drysdale, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) disrupting one of the largest fields in modern medicine is a key component of their growth strategy…
“We are focused on addressing the mental health crisis and transforming the treatment landscape.”
– Doug Drysdale, Cybin CEO
To accelerate the growth of the company, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) is deploying a “three pillar” strategy…
- Pillar #1: New Drug Discovery Platform, includes applying well-known scaffolds including Psilocybin, DMT, and MDMA…
- Pillar #2: Proprietary Drug Delivery And Formulation using inhalation, sublingual & ODT, and extended-release formulation delivery systems that have the potential to reduce side effects and to control exposure…
- Pillar #3: Leveraging Tech While Providing New Treatment Regimens For Clinicians, deploying software-based platforms, novel neuroimaging technology, and machine learning based data analytics…
Don’t expect Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) to remain “tiny” once the news about their revolutionary medical breakthroughs goes mainstream.
Investors looking for early opportunities in psychedelic medicine should move quickly on Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) and establish a position before the wall or retail and institutional money starts moving in on the opportunity.
CLICK HERE NOW for in-depth investor information on Cybin and the opportunities in the growing psychedelic medicine space.
References
1 (https://www.who.int/whr/2001/media_centre/press_release/e n/) & (https://www.mirror-mirror.org/eating-disordersstatistics. htm) & (https://drugfree.org/learn/drug-and-alcoholnews/ researchers-release-first-report-worldwide-addictionstatistics/)
2 https://www.who.int/whr/2001/media_centre/press_release/en/
3 (1)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007565/
4 Kyzar, E. J.; Nichols, C. D.; Gainetdinov, R. R.; Nichols, D. E.; Kalueff, A. V., Psychedelic Drugs in Biomedicine. Trends Pharmacol Sci 2017, 38 (11), 992-1005.
Be part of the Future
Enter your email below to get your free early investor report on Cybin, Inc.